COCP - Cocrystal cleared to run Phase 1 trial for COVID-19 drug in Australia
2023-05-31 08:27:50 ET
Cocrystal Pharma ( NASDAQ: COCP ), a biotech focused on antiviral therapies, announced Wednesday that the company received approval to conduct a Phase 1 trial for its oral COVID-19 therapy CDI-988 in Australia.
The permission from the Australian Human Research Ethics Committee (HREC) paves the way for Cocrystal ( COCP ) to test the protease inhibitor in a randomized, double-blind, placebo-controlled trial involving healthy volunteers.
James Martin, co-CEO and CEO, noted that Cocrystal ( COCP ) has already established an Australian unit and partnered with a local contract research organization for the company’s influenza A Phase 1 study.
“We are excited to have accomplished this milestone and look forward to initiating our CDI-988 clinical program as an oral treatment for patients with COVID-19, as well as demonstrating our drug discovery platform technology capabilities,” President and co-CEO Sam Lee said.
More on Cocrystal
- Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19
- Cocrystal Pharma completes $4M equity offering priced ATM
For further details see:
Cocrystal cleared to run Phase 1 trial for COVID-19 drug in Australia